Camzyos (mavacamten) / BMS - LARVOL DELTA

Incidence of Ventricular Arrhythmias and Sudden Cardiac Death with Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. (PubMed, J Pers Med) - " We conducted a meta-analysis of RCTs evaluating mavacamten or aficamten in patients with HCM. No statistically significant increase in ventricular arrhythmia or SCD risk was observed. However, limited events and short follow-up preclude firm conclusions regarding the arrhythmic safety of myosin inhibitors."

Journal • Retrospective data • Review • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Ventricular Tachycardia

Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy. Reply. (PubMed, N Engl J Med) - No abstract available

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

A computationally informed framework for lipid-based formulation developability: Integrating predictive models with case studies. (PubMed, J Pharm Sci) - "A database of >200 FDA-approved oral drugs (2010-2023) was screened through the computational framework, and four case studies (dapagliflozin, mavacamten, ospemifene, flibanserin) illustrate the framework's ability to classify risk and guide formulation decisions. This integrated approach enables rapid, data-driven formulation decisions, reducing reliance on trial-and-error methods and supporting early-stage development of PWSDs. By coupling computational predictions with targeted experimental validation, the framework offers a practical roadmap for accelerating LBF adoption and improving R&D efficiency."

Journal

Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy. (PubMed, N Engl J Med) - No abstract available

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy. (PubMed, N Engl J Med) - No abstract available

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

Role of Provocation and Exercise Imaging for the Identification of Candidates for Cardiac Myosin Inhibitors. (PubMed, ESC Heart Fail) - "Patients requiring exercise echocardiography to document qualifying LVOTO do not exhibit a milder disease phenotype and derive similar treatment benefits from mavacamten compared to those with resting or Valsalva-provoked obstruction. Exercise echocardiography identifies a substantial proportion of symptomatic HCM patients with significant LVOTO missed by resting assessment and is essential for guiding treatment eligibility."

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy. (PubMed, N Engl J Med) - No abstract available

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Baseline Characteristics, Drug Exposure, and Outcomes in an Exploratory Analysis From ODYSSEY-HCM. (PubMed, J Am Coll Cardiol) - No abstract available

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

Assessing Aortic Stenosis Severity in Dynamic Left Ventricular Outflow Obstruction Using Echo Doppler. (PubMed, CASE (Phila)) - "• The use of HPRF reduces aliasing at the cost of introducing some range ambiguity. • Continuity equation may be considered using the volumetric LVSV."

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Mavacamten and atrial fibrillation: assessing the risk through FAERS and meta-analysis. (PubMed, BMC Cardiovasc Disord) - No abstract available

Journal • Retrospective data • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

One- and two-year structural changes of mavacamten therapy in hypertrophic obstructive cardiomyopathy: a case report with serial comprehensive CMR demonstrating continuous reverse remodelling. (PubMed, Eur Heart J Case Rep) - "A 39-year-old male with symptomatic HOCM refractory to bisoprolol and disopyramide was initiated on mavacamten therapy. This case indicates that mavacamten leads to longer-term cardiac remodelling up to two years after initiation of treatment, beyond early haemodynamic improvement and reduction of LVOT obstruction. These observations nurture additional studies to investigate longer-term effects on myocardial structure, function, and interstitial fibrosis."

Journal • Cardiomyopathy • Cardiovascular • Fibrosis • Hypertrophic Cardiomyopathy • Immunology • Obstructive Hypertrophic Cardiomyopathy

Mavacamten Derivatives Significantly Ameliorate Lipopolysaccharide-Induced Acute Lung Injury, Partly by Modulating Nuclear Factor Kappa‑B Signaling. (PubMed, ACS Pharmacol Transl Sci) - "Histopathological examination revealed that 5d and 5o markedly alleviated LPS-induced lung (alveolar edema, wall thickening) and heart (myocardial inflammation) abnormalities. Mechanistic findings demonstrate that compounds 5d and 5o effectively reduced the LPS-induced inflammation and tissue injury by modulating NF-κB signaling in both in vitro and in vivo conditions, highlighting their translational potential as therapeutic candidates for the treatment of ALI/ARDS."

Journal • Acute Lung Injury • Acute Respiratory Distress Syndrome • Inflammation • Pulmonary Disease • Respiratory Diseases • CAV1 • CCL2 • IL1B • TNFA

Evolving strategies in obstructive hypertrophic cardiomyopathy: myosin inhibitors as monotherapy compared with beta-blockers. (PubMed, Heart Fail Rev) - "Cardiac myosin inhibitors (CMIs), including mavacamten and aficamten, represent a new therapeutic class targeting the hypercontractile sarcomere. BBs remain clinically relevant for specific patient subgroups, but the advent of CMIs marks a paradigm shift from symptomatic relief toward targeted disease modification in oHCM. [Image: see text]"

Journal • Monotherapy • Review • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Targeting Myocardial Energetics in Nonobstructive Hypertrophic Cardiomyopathy (nHCM): The Role of Ninerafaxstat. (PubMed, J Cardiovasc Pharmacol) - "Clinical trials of novel agents, including myosin inhibitors (aficamten, mavacamten) and metabolic modulators, highlight ninerafaxstat's unique potential. Ninerafaxstat represents a paradigm shift toward precision medicine in nHCM, offering a metabolic foundation for combination strategies. Future Phase 3 trials must validate long-term benefits on functional capacity, metabolic markers, arrhythmia risk, and survival, positioning ninerafaxstat as a cornerstone therapy for restoring cardiac energetics in nHCM."

Journal • Cardiomyopathy • Cardiovascular • Gene Therapies • Hypertrophic Cardiomyopathy • Metabolic Disorders • Non-obstructive Hypertrophic Cardiomyopathy

Obstructive Hypertrophic Cardiomyopathy With Degenerative Mitral Regurgitation: A New Treatment Strategy Using Mavacamten Combined With M-TEER. (PubMed, JACC Case Rep) - "For oHCM patients with concomitant degenerative mitral regurgitation, the combined treatment of mavacamten and M-TEER represents a potential therapeutic option with complementary mechanisms."

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Cardiac Myosin Inhibitors and Incident Atrial Fibrillation in Hypertrophic Cardiomyopathy: Systematic Review and Meta-Analysis. (PubMed, J Cardiovasc Electrophysiol) - "Randomized evidence to date does not demonstrate an increased AF risk with CMIs. Differences between RCT populations and real-world cohorts, including restrictive AF eligibility criteria, lower baseline atrial remodeling, and limited rhythm surveillance may explain discordant observational findings and highlight the need for longitudinal monitoring in clinical practice."

Journal • Retrospective data • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Mavacamten In Symptomatic Adolescent Patients With Obstructive Hypertrophic Cardiomyopathy: Results From The Phase 3 Scout-HCM Trial (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Late-breaking abstract • P3 data • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

WHEN ENERGY DRINKS AREN'T SO ENERGIZING: GRAPEFRUIT-MAVACAMTEN INTERACTION LEADING TO REDUCED EJECTION FRACTION (ACC 2026) - "This case highlights the importance of patient counseling regarding dietary interactions with novel cardiovascular therapies. Grapefruit juice inhibits CYP3A4, markedly increasing mavacamten levels, and the patient's otherwise stable LVEF rapidly declined only after consuming these beverages. Mavacamten carries a boxed warning for systolic dysfunction, making avoidance of such interactions critical."

Cardiomyopathy • Cardiovascular • Dyslipidemia • Hypertension • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy • Pulmonary Disease • CYP2C19 • CYP3A4

LONG-TERM MANAGEMENT OF STANDARD-OF-CARE THERAPY IN PATIENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY TREATED WITH MAVACAMTEN (ACC 2026) - "To evaluate changes in AVNB exposure, beta blocker total daily doses were converted to metoprolol succinate equivalents. Treatment with mavacamten enabled decreases in background AVNB therapy in patients with symptomatic oHCM."

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

CARDIAC MYOSIN INHIBITORS IN SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: A META-ANALYSIS OF RCTS INCLUDING THE MAPLE-HCM TRIAL (ACC 2026) - "Cardiac myosin inhibitors (CMIs) (mavacamten and aficamten) reduce sarcomeric activity. CMIs reduce LVOT obstruction, improve symptoms, biomarkers, and quality of life in oHCM with preserved safety, establishing them as the first disease-specific therapy in the modern management of oHCM."

Retrospective data • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Hypertension • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy • Pulmonary Disease

DOUBLE JEOPARDY: SURGICAL AORTIC VALVE REPLACEMENT IN AN OCTOGENARIAN COMPLICATED BY SEVERE PATIENT-PROSTHESIS MISMATCH AND LVOT OBSTRUCTION (ACC 2026) - "In high risk octogenarians with severe PPM and LVOTO, mavacamten may be a reasonable therapeutic option. Preventive strategies remain essential to avoid severe PPM."

Clinical • Amyloidosis • Cardiovascular • Pulmonary Disease

EFFICACY OF MAVACAMTEN IN HYPERTROPHIC CARDIOMYOPATHY: AN UPDATED META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (ACC 2026) - "Mavacamten confers diastolic and biomarker benefits in nHCM without functional improvement, whereas exercise capacity and quality of life also improves in oHCM, reflecting greater therapeutic effect."

Retrospective data • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

REAL-WORLD EVIDENCE FROM THE MARVEL-HCM MULTICENTER STUDY OF MAVACAMTEN — A SEX-BASED ANALYSIS OF BASELINE CHARACTERISTICS AND CARDIAC STRUCTURAL AND FUNCTIONAL CHANGES (ACC 2026) - "In this RW study, females had greater disease severity at baseline than males. Regardless of sex, mavacamten was effective and the safety profile was consistent with previous reports."

Clinical • HEOR • Real-world • Real-world evidence • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

UNMASKING THE HIDDEN GRADIENT: DYNAMIC LVOTO REVEALING HYPERTROPHIC CARDIOMYOPATHY IN SEVERE ANEMIA (ACC 2026) - "Disopyramide was initiated but caused hypotension, so carvedilol and diltiazem were started, lowering the resting gradient to 33 mmHg though provoked obstruction persisted...Given age and comorbidities, mavacamten was started with echocardiographic follow-up. Physiologic stress may transiently unmask LVOTO, but persistent obstruction despite correction of triggers should prompt evaluation for HOCM or other structural disease. This case highlights the need to distinguish transient obstruction from true anatomic substrates to guide disease-specific therapy."

Anemia • Cardiomyopathy • Cardiovascular • Hematological Disorders • Hypertrophic Cardiomyopathy • Hypotension • Obstructive Hypertrophic Cardiomyopathy

MAVACAMTEN IN NONOBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: BIOMARKER BENEFIT WITHOUT FUNCTIONAL IMPROVEMENT - A SYSTEMATIC REVIEW AND META-ANALYSIS OF 639 PATIENTS (ACC 2026) - "Mavacamten reduces NT-proBNP in nHCM but fails to improve exercise capacity, symptoms, or quality of life. Its use is limited by reversible systolic dysfunction and higher discontinuation rates, underscoring the need to identify subgroups most likely to benefit and to implement monitoring strategies. Routine use should be cautious and individualized, focusing on safety monitoring."

Biomarker • Retrospective data • Review • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy